Genotype-based diagnostics for antibiotic resistance represent a promising alternative to 21 empiric therapy, reducing inappropriate and ineffective antibiotic use. However, because 22 103
such assays infer resistance phenotypes based on the presence or absence of known 23 genetic markers, their utility will wane in response to the emergence of novel resistance. 24
Maintenance of these diagnostics will therefore require surveillance designed to ensure 25 early detection of novel resistance variants, but efficient strategies to do so remain to be 26 defined. Here, we evaluate the efficiency of targeted sampling approaches informed by 27 patient and pathogen characteristics in detecting genetic variants associated with 28 antibiotic resistance or diagnostic escape in Neisseria gonorrhoeae, focusing on this 29 pathogen because of its high burden of disease, the imminent threat of treatment 30 resistance, and the use and ongoing development of genotype-based diagnostics. We 31
show that incorporating patient characteristics, such as demographics, geographic 32 regions, or anatomical sites of isolate collection, into sampling approaches is not a reliable 33 strategy for increasing variant detection efficiency. In contrast, sampling approaches 34 informed by pathogen characteristics, such as genomic diversity and genomic 35 background, are significantly more efficient than random sampling in identifying genetic 36 variants associated with antibiotic resistance and diagnostic escape. 37
Introduction: 39
Nucleic acid-based diagnostics that enable rapid pathogen identification and 40 prediction of drug susceptibility profiles can improve clinical decision-making, reduce 41 inappropriate antibiotic use, and help address the challenge of antibiotic resistance 1-3 . 42
However, the sensitivity of such diagnostics may be undermined by undetected genetic 43 variants 4-12 . Pathogen surveillance programs aimed at early detection of novel variants 44 are crucial to ensuring the clinical utility and sustainability of these diagnostics. 45
Use of traditional nucleic acid amplification tests (NAATs) for pathogen 46 identification and genotype-based diagnostics for antibiotic resistance can select for 47 genetic variants that escape detection 13 . Mutations and/or deletions at the NAAT target 48 locus that cause an amplification failure have arisen in Neisseria gonorrhoeae, Chlamydia 49 trachomatis, Staphylococcus aureus, and Plasmodium falciparum, resulting in false 50 negative diagnostic errors only detected when using another diagnostic platform [5] [6] [7] 11 . 51
Diagnostic escape associated with genotype-based diagnostics for antibiotic resistance 52 are the result of resistance-conferring variants (e.g., mutations or accessory genes) not 53 accounted for in the diagnostic's panel of resistance markers 4 and require phenotypic 54 testing to be uncovered. 55
We recently presented a framework to quantify the sampling rate for early 56 detection of novel antibiotic resistance variants, defining the number of isolates that would 57 need to undergo confirmatory phenotyping from those predicted by genotype to be 58 susceptible 14 . Underlying this model are assumptions of unbiased sampling across a 59 population and independence among all isolates. However, these assumptions may not 60 hold in practice, as some subsets of the population (e.g., demographics and/or geographic regions) may be more likely to be sampled than others, and clonal 62 transmission may result in repeated sampling of closely related isolates [15] [16] [17] [18] . The real-63
world application of this model may also be challenging for pathogens with high case 64 incidence, such as N. gonorrhoeae, as the cost of phenotyping required by this model for 65 timely detection of novel resistance variants is likely to be high 14 . 66 Implementing a practical surveillance system thus requires improving efficiency 67 over unbiased testing by prioritizing samples in which novel diagnostic escape variants 68 are most likely to be found. There are numerous hypotheses for how to focus sampling 69 and most quickly identify these variants. Novel variants may be more likely to emerge or 70 spread in certain anatomical niches, demographics, or geographic regions [19] [20] [21] [22] , some of 71 which may be systematically under-sampled 23 and thus may provide a basis for sampling 72 priority. Data on such characteristics may be obtained from metadata recorded during 73 clinical encounters. Alternatively, they may be inferred from pathogen genomic data. 74
Isolates or clades that are genetically divergent from the majority of isolates in a 75 population may reflect travelers, their contacts, or otherwise under-sampled lineages 24-76 27 . Some pathogen genomic backgrounds may be more conducive to the evolution of 77 novel resistance mechanisms 28 , and markers of these genomic backgrounds (e.g., 78
variants associated with a range of resistance mechanisms and/or resistance to other 79 drugs) may help improve sampling efficiency. Similarly, given historical patterns of 80 antibiotic use, novel resistance may emerge on a background of existing resistance 29 . 81
Thus, genetic markers of resistance to certain drugs may facilitate identification of 82 lineages more likely to have experienced selective pressures leading to emergence of 83 novel resistance variants. 84
Here, we test the performance of sampling strategies informed by these 85 hypotheses using N. gonorrhoeae surveillance data. N. gonorrhoeae offers a useful 86 model, given the increasing drug resistance and recent focus on developing sequence-87 based resistance diagnostics 2,30 . We present targeted sampling approaches informed by 88 patient (i.e., demographics, anatomical site of isolate collection, geographical region, 89 recent travel history, or sex worker status) and pathogen (i.e., phylogenetic or genomic 90 background) information. We assess the efficiency of each of these strategies to detect 91 rare (<10% prevalence) resistance variants associated with current or recent first-line 92 recommended antibiotics (i.e., azithromycin [AZM] and extended spectrum 93 cephalosporins [ESCs]), as well as rare genetic variants associated with diagnostic 94 escape, across five genomic surveys with various demographic, geographic, and 95 temporal ranges. We show that phylogeny-and genomic background-aware sampling 96 approaches can increase the detection efficiency of known variants over random 97 sampling, whereas patient feature-based sampling approaches do not. Our results 98 suggest that implementation of such targeted sampling approaches into surveillance 99 programs may reduce the number of cases of novel resistance that occur before it is 100 detected, as well as the resources required to undertake surveillance, compared to 101 random sampling of a population. 102 18% of isolates with reported anatomical site of collection in datasets 1 and 2, 114 respectively. This suggests either sampling bias across anatomical sites in at least one 115 of the datasets or substantial variation across the two study populations in prevalence of 116 pharyngeal gonococcal infections. Similarly, the geographic distribution of isolates in 117 dataset 3 was significantly different from the reported case incidence across countries 118 ( Targeted sampling based on patient characteristics.
We investigated whether sampling evenly across demographic groups (demography-125 aware sampling), anatomical sites of isolate collection (niche-aware sampling), and 126 geographic regions (geography-aware sampling) increased detection efficiency of 127 resistance variants by ameliorating some of the demographic, niche, or geographic 128 sampling biases. We further investigated whether preferentially sampling patients with 129 recent overseas sexual encounters or recent sex work, two characteristics hypothesized 130 to be associated with the introduction and/or increased transmission of resistance 19, 21, 22 , 131 increased the detection efficiency of resistance variants. To do so, we simulated and 132 compared the detection efficiency of three genetic resistance variants ( 
a Given the >10% prevalence of RplD G70D in datasets 1 and 4 and penA XXXIV in 138 dataset 3, these variants were excluded from sampling simulations. 139 AZM, azithromycin; ESC, extended-spectrum cephalosporin; CRO-RS, ceftriaxone 140 reduced susceptibility; CFX-R, cefixime resistance 141 142
The detection efficiency was not improved by demography-, niche-, geography-143 aware sampling compared to random sampling for any of the resistance variants (Table S3 , Fig. 1) . In several cases, detection efficiency significantly decreased in demography-145 or geography-aware sampling compared to random sampling, reflecting enrichment of 146 the resistance variant in the overrepresented demographic or geographic region. 147
However, no significant association between a given resistance variant and demographic 148 group was observed across both dataset 1 and dataset 2, and no demographics or 149 geographic regions were significantly enriched for all variants (Table S1), suggesting that 150 preferential sampling of any of these demographics or geographic regions would not be 151 a reliable strategy for increasing novel variant detection efficiency. For example, while 152
penA XXXIV was significantly enriched in MSM compared to men who have sex with 153 women and women who have sex with men (MSW/WSM) patients in dataset 2 (P < 0.003, 154
Fisher's exact test), there was no significant difference in the proportions of MSM and 155 MSW/WSM with penA XXXIV in dataset 1 (P = 0.461, Fisher's exact test). Similarly, while 156 the AZM-R-associated RplD G70D mutation in dataset 3 was at highest prevalence in 157 patients from Malta and Greece (10% and 6.25%, respectively) and absent from patients 158 from Denmark, the AZM-R-associated 23S C2611T variant was at highest prevalence in 159 patients from Denmark (5.45%) and absent from patients from Malta or Greece. 160 penA XXXIV (E-F) in datasets 1 and 2. In datasets 1 and 2, targeted sampling was 166 informed by demographic (gender and sexual behavior) and anatomical site of isolate 167 collection (niche) information (A, C, and E), and in datasets 3 and 4, targeted sampling 168 was informed by country or prefecture of sample collection (B, D, and F). Dot colors 169
indicate the sampling approach, and asterisks indicate a significant difference (P < 0.05 170
by Mann-Whitney U test) in detection efficiency between the demography-, niche-or 171 geography-aware approach compared to random sampling (*P < 0.05, **P < 0.01, ***P < 172 0.001; red asterisks indicate significantly lower detection efficiency of demography-or 173
geography-aware approaches compared to random sampling). Note that sampling 174 simulations were not performed for RplD G70D in datasets 1 and 4 or for penA XXXIV in 175 dataset 3 as prevalence of the variants in these datasets was >10%. n.s., not significant 176 Isolates from patients with recent overseas sex were associated with significantly 180 longer terminal branches compared to patients that had only engaged in sex locally ( Fig.  181   S1) , in support of the hypothesis that international travel may be associated with the 182 importation of novel or divergent strains, or, more generally, that isolates from travelers 183 may be more likely to be associated with under-sampled lineages. Preferentially sampling 184 from patients with recent overseas sex significantly improved detection efficiency of the 185 RplD G70D mutation and the penA XXXIV allele, as these were at marginally higher 186 prevalence in isolates from patients with recent overseas sex compared to those from 187 patients who had only engaged in sex locally (3.03% overseas vs. 0.98% local and 2.02% 188 overseas vs. 1.67% local, respectively, P = 0.090 and 0.683, respectively, by Fisher's 189 exact test for both variants). In contrast, the 23S C2611T mutation was exclusively 190 present in isolates from patients who had engaged in sex locally (Tables S1 and S4). the RplD G70D mutation and the penA XXXIV allele were not significantly improved by 197 preferentially sampling from sex workers (Tables S1 and S4). 198
Together, these results suggest that while targeted sampling based on patient 199 characteristics may increase detection efficiency of some novel variants, it is difficult to 200 predict which groups to target for all potential novel variants. 201
202
Targeted sampling based on genetic diversity. 203
To assess whether preferential sampling of lineages that are divergent from those that 204 have been previously sampled may increase detection efficiency of genetic resistance 205 variants over random sampling, we simulated phylogeny-aware sampling using two 206 methods: 1) maximization of the phylogenetic distance covered with each isolate sampled 207 (distance maximization) and 2) even sampling across phylogenetic lineages (clonal 208 group). 209
While the distance maximization approach increased detection efficiency 210 compared to random sampling for some variants, there were numerous instances in 211 which this approach, which led to preferential sampling of isolates associated with long 212 branches, substantially decreased detection efficiency (Fig. 2, Table S5 ). 213 XXXIV (C) in datasets 1-5. Note that sampling simulations were not performed for RplD 219 G70D in datasets 1 and 4 or for penA XXXIV in dataset 3 as prevalence of the variants in 220 these datasets was >10%. Maximum-likelihood phylogenies produced from 221 pseudogenome alignments (with predicted regions of recombination removed) of isolates 222 from dataset 4 (D) and dataset 2 (E). Presence or absence of the 23S rRNA C2611T 223 mutation (in at least 2/4 alleles) and the mosaic penA XXXIV allele is indicated by colored by Mann-Whitney U test) in detection efficiency between the phylogeny-aware approach 230 compared to random sampling (*P < 0.05, **P < 0.01, ***P < 0.001; red asterisks indicate 231 significantly lower detection efficiency of the phylogeny-aware approach compared to 232 random sampling, and green asterisks indicate significantly higher detection efficiency of 233
the phylogeny-aware approach compared to random sampling). n.s., not significant at a 234 = 0.05.
236
The clonal group sampling approach prevents repeated sampling of very closely 237 related isolates until all unique phylogenetic clusters have been sampled. Thus, for both 238 rare variants that are clonally distributed and rare variants that are more randomly 239 dispersed throughout the phylogeny (e.g., penA XXXIV and 23S rRNA C2611T mutations, 240 respectively, Table 2 ), this approach increases detection efficiency in cases where 1) 241 there is substantial clonality among isolates and 2) a substantial proportion of variant-242 positive isolates do not occur in clonal lineages dominated by variant-negative isolates 243 ( Fig. 2E) . In such datasets, effectively collapsing large variant-negative lineages into a 244 single representative increases the effective prevalence of the variants and thus the 245 detection efficiency of the clonal group approach compared to random sampling. The 246 clonal group sampling approach significantly decreased detection efficiency in only one 247 instance (i.e., the 23S rRNA C2611T variant in dataset 4, Table S5 ), where all isolates 248 with the variant appeared in large clonal lineages of predominately variant-negative 249 isolates (Fig. 2D) . 250
In cases where the clonal group sampling approach did not perform better than 251 random sampling, adjusting the threshold for clonal grouping and/or a marginal increase 252 in the prevalence of variant-positive isolates could elevate the relative performance of this 253 targeted approach. We chose 134 SNPs as an example threshold for clonal grouping, as 254 it represents the lower 95% confidence interval of the mean of SNP distances between 255 each CFX-R resistant and the closest susceptible isolate in datasets 1-5 (see Methods). 256
In the case of the 23S rRNA C2611T variant in dataset 4, the average prevalence of the 257 variant across clonal groups (i.e., the total number of variant-positive isolates, counting 258 each variant-positive isolate as [1 / [1 + the total number of additional isolates that are £ 259 134 SNPs of the isolate]], divided by the number of clonal groups) is 0.005, lower than 260 the actual prevalence of 0.012. However, if the threshold for clonal grouping was lower in 261 this instance (e.g., 50 SNPs), the effective prevalence of the variants would be 0.020, 262 greater than the actual prevalence of 0.012. Similarly, using the 134 SNP threshold, if 263 one additional isolate that was > 134 SNPs from any other isolates in this dataset had the 264 23S rRNA C2611T mutation, the average prevalence of the variant across clonal groups 265 would be 0.036, greater than the actual prevalence of 0.016, and thus the clonal group 266 approach would outperform random sampling. 267
To further assess the performance of phylogeny-aware sampling in the context of 268 rare genetic variants that may have emerged in response to diagnostic pressure, we 269 simulated random and phylogeny-aware sampling to assess detection efficiency of an 270 additional set of variants. Specifically, we assessed a panel of N. gonorrhoeae diagnostic 271 escape variants: the 16S rRNA C1209A mutation, the N. meningitidis-like porA, and the 272 cppB deletion, all of which have been previously associated with diagnostic failure 7-10 273 and were present in one or more of datasets 1-5 at low prevalence ( Table 3) . The G168A 274 mutation in the primer binding region of DR-9A, the target of the COBAS 4800 CT/NG 275 (Roche) diagnostic, has not previously been documented but was present in 0.1% of 276 strains from dataset 2. All of the diagnostic-associated variants assessed appeared in 277 divergent backgrounds and were thus detected more efficiently by phylogeny-aware 278 sampling compared to random sampling ( Fig. 2F-I, Table S6 ). Like the results from the 279 simulations based on resistance variants, the distance maximization approach maximized 280 detection efficiency for some of the diagnostic-associated variants, but superiority of this 281 approach to random sampling was not consistent across all variants. However, the clonal 282 group approach performed significantly better than random sampling for all diagnostic-283 associated variants across all datasets. 284 285 
288
The relative performance of the clonal group sampling approach compared to 289 random sampling was generally consistent across multiple thresholds based on 290 pseudogenomes (i.e., £ 134 SNPs, £ 422 SNPs, and fastBAPS groups); relative 291 performance of clonal group sampling using MLSTs, however, was less consistent and 292 was significantly worse than random sampling for several variants (Fig. S2, Tables S5-293   S6) . Together, these results suggest that preferentially sampling isolates that, based on 294 whole genome sequencing (WGS), are phylogenetically divergent from those that have 295 previously been sampled may increase detection efficiency of novel resistance variants. 296 297
Targeted sampling based on genetic markers. 298
Multiple drug resistance is more common in pathogenic bacteria than one would expect 299 from the product of frequencies of resistance to individual drugs 43,44 . This suggests that 300 novel resistance mechanisms might be more likely to arise and spread in bacterial strains 301 that are already resistant to other drugs, a phenomenon that has been documented in N. 302 gonorrhoeae 45 . It may therefore be fruitful to look for novel resistance variants for one 303 drug in genetic backgrounds that are resistant to other drugs. It may be similarly effective 304 to sample preferentially isolates with genetic markers that have been associated with a 305 range of resistance mechanisms (e.g., through epistatic interactions with other genetic 306 variants) within and/or across different antibiotics when screening for a novel resistance States 47 , and more recent years in other countries 48-50 , we investigated whether 310 resistance to ESCs is significantly more likely to occur in the background of genotypic 311 ciprofloxacin resistance (i.e., in strains with the GyrA S91F mutation). Similarly, as 312 mutations at positions 120 and/or 121 in PorB, the major outer membrane protein in 313 gonococci, have been associated with resistance to a range of drugs from multiple 314 classes 51 , we investigated whether resistance to ESCs is significantly more likely to occur 315 in strains with PorB 120 and/or 121 mutations. Isolates with CRO-RS and CFX-R were 316 significantly more likely to have the GyrA S91F mutation and the PorB G120 and/or A121 317 mutations than the wild-type GyrA S91 or wild-type PorB G120/A121 (P < 0.001, Fisher's 318 exact test, Fig. 3A-B) . Further, both GyrA S91F and PorB G120 and/or A121 mutations 319 occurred across a range of ESC resistance locus haplotypes ( Fig. 3C-D) . For all datasets 320 with CRO-RS or CFX-R isolates, detection efficiency of both variants was significantly 321 increased by only sampling isolates with the GyrA S91F mutation or the PorB G120 and/or 322 A121 mutations ( Fig. 3E-F, Table S7 ). Together, these results suggest that preferential 323 sampling of isolates with certain genetic markers, including markers of resistance to 324 previous first-line antibiotics, may increase the detection efficiency of novel resistance 325 variants. 326 isolates, cefixime resistant (CFX-R) isolates, and cefixime susceptible (CFX-S) isolates 331
with GyrA S91F and GyrA S91 wild-type alleles (A) and with PorB G120 and/or A121 332 mutations and PorB G120 and A121 wild-type alleles (B) across datasets 1-5. Bar charts 333
showing the number of (C) CRO-RS and (D) CFX-R isolates with each haplotype, along 334
with heatmaps showing the presence or absence of the GyrA S19F mutation, the PorB 335 G120 and/or A121 mutations, and other alleles at loci previously associated with 336 extended spectrum cephalosporin resistance. Bar the phylogeny-aware approach compared to random sampling (*P < 0.05, **P < 0.01, 343 ***P < 0.001; green asterisks indicate significantly higher detection efficiency of the 344 genomic background-aware approach compared to random sampling). 345 346
Discussion 347
With sequencing becoming more integral to routine pathogen surveillance and 348 diagnostics, it is important to ensure that models mapping genotypic information to 349 expected pathogen phenotype and/or clinical outcome are comprehensive and current 52 . 350
In the case of genotype-based diagnostics, sustained phenotypic surveillance is crucial 351 for identifying resistance variants that have recently emerged and/or increased in 352 prevalence from previously undetected levels. While effective incorporation of patient 353 metadata into surveillance strategies may be challenging, availability and incorporation 354 of information on pathogen characteristics (e.g., pathogen genomic data) into surveillance 355 programs may ultimately decrease the cost of surveillance to maintain the sensitivity of 356 these diagnostic tools. 357
Collection of patient metadata, including demographic and geographic information, 358 is crucial to understanding the epidemiology of drug resistance. However, it may be 359 difficult to obtain data on the relevant patient features, and the predictive power of such 360 features may rapidly decay because of patient mobility and interactions 53 . While 361 availability of patient metadata varied across the datasets assessed, our results suggest 362 that while incorporation of patient metadata into sampling strategies may increase 363 detection efficiency for some novel resistance variants, it may be difficult to generalize for 364 all potential novel resistance variants. It is possible that targeted sampling based on 365 patient characteristics may be more reliable in the context of pathogens, antibiotic, and/or 366 patient characteristics not assessed here. 367
Incorporation of WGS into routine pathogen surveillance by public health agencies 368 54,55 may facilitate use of genomic information in phenotypic sampling strategies, 369 particularly with emerging metagenomic approaches that do not require bacterial culture 370 56 . Our results show that phylogeny-aware sampling, particularly the clonal group 371 approach, which reduces the amount of repeated sampling of closely related isolates, 372 significantly improved detection efficiency over random sampling for multiple resistance 373 and diagnostic-associated variants. Further, identification of and preferential sampling of 374 isolates with genetic markers that are consistently predictive of resistance across a range 375 of mechanisms, including those associated with resistance to other drugs, may 376 supplement phylogeny-aware sampling to further optimize detection efficiency of novel 377 variants. However, the utility of sampling based on genetic markers of other resistance 378 mechanisms will likely vary substantially across different drugs and be influenced by 379 future treatment guidelines. 380
While the clonal group sampling approach increased detection efficiency for the 381 resistance and diagnostic escape variants assessed here, it may be difficult to determine 382 the most effective and reliable metric or threshold for clonal grouping, especially as this 383 is likely to vary across different clinical populations, antibiotics, and bacterial species. 384
Detection efficiency was generally consistent across the two SNP thresholds and 385 fastBAPS groupings based on WGS. However, performance of the clonal group approach 386 using MLSTs was inconsistent and, in some instances, worse than random sampling, 387 likely due to the shortcomings of MLST compared to WGS-based approaches in 388 distinguishing between AMR variant-positive clades and more distantly-related variant-389 negative clades in species such as N. gonorrhoeae 34 . This suggests that this approach 390 is sensitive to similarity thresholds and that a low SNP threshold based on WGS 391 assemblies may be the most appropriate approach, particularly in a population where 392 there is expected to be substantial clonality among isolates and thus, even with a low 393 threshold, detection efficiency will be improved by the clonal group approach. More 394 broadly, surveillance incorporating WGS rather than MLST loci alone may further promote 395 NAAT sustainability by enabling screening for variants with previously undetected 396 mutations in target loci, such as the N. gonorrhoeae DR-9A G168A variants, that may be 397 associated with diagnostic escape. 398
We have assessed these targeted sampling approaches in detection of multiple 399 resistance variants across a range of populations, but these represent only a fraction of 400 resistance mechanisms in a single species. These findings may extend to other antibiotics 401 and bacterial species. For example, given the high degree of clonality among M. 402 tuberculosis isolates and the significant variation in prevalence of drug resistance and 403 resistance-conferring genotypes across clonal groups 57,58 , the clonal group sampling 404 approach may similarly improve detection efficiency of novel resistance variants in M. 405 tuberculosis. For species in which drug resistance is primarily acquired through gene 406 acquisition, it is unclear if phylogeny-aware sampling based on the core genome will 407 improve detection efficiency of novel variants. K-mer distances 59,60 may provide a more 408 practical alternative generalizable to more resistance mechanisms associated with gene 409 acquisition. Further, the requirement of confirmatory phenotyping to identify novel 410 resistance may not extend to pathogens that are expected to be associated with reliably-411 identifiable treatment failures, as for these pathogens, identification of treatment failure 412 likely represents the most efficient method of novel resistance variant detection 61 . 413
However, for other pathogens, such as N. gonorrhoeae 62 , treatment failures may go 414 undetected for reasons including partial abatement of symptoms or long treatment 415 regimens. Ultimately, as genotype-based diagnostics for antibiotic resistance become 416 available for more species, it will be important to assess the efficiencies of these 417 approaches across pathogens with different clinical, epidemiological, and evolutionary 418
paradigms. 419
Since we lack the datasets to assess targeted sampling of variants from the time 420 they first emerged in a population, any associations we observed between the variants 421 and patient or pathogen features do not necessarily reflect those around the time of 422 emergence. Thus, more longitudinal epidemiological and genomic studies, particularly 423 after the implementation of genotype-based diagnostics, are necessary to better 424 characterize patterns of novel resistance emergence and inform targeted surveillance 425
approaches. 426
The phylogeny-aware sampling approaches presented here are based on the 427 assumption that genomic data will be available for the pool of potential isolates from 428 incident cases that may undergo confirmatory phenotyping. However, using information 429 on isolate features to increase surveillance efficiency may be feasible even in the absence 430 of mass prospective sequencing. For example, under the general assumption that novel 431 resistance variants are more likely to appear in underrepresented lineages, phylogeny-432 aware surveillance could be paired with a diagnostic approach such as genomic neighbor 433 typing 56 , where any isolates with either susceptible or low confidence calls that appear
